214 related articles for article (PubMed ID: 11036960)
1. Paclitaxel-induced remission in docetaxel-refractory anthracycline-pretreated metastatic breast cancer.
Suzuma T; Sakurai T; Yoshimura G; Umemura T; Tamaki T; Naito Y
Anticancer Drugs; 2000 Aug; 11(7):569-71. PubMed ID: 11036960
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel in anthracycline-resistant metastatic breast cancer.
Hui YF; Ignoffo RJ
Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
[TBL] [Abstract][Full Text] [Related]
3. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Ravdin PM
Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
[TBL] [Abstract][Full Text] [Related]
4. [Docetaxel therapy against anthracycline resistant breast cancer].
Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa Y; Naito Y; Suzuma T; Tanino H
Gan To Kagaku Ryoho; 1999 May; 26(6):781-8. PubMed ID: 10410147
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel in doxorubicin-resistant metastatic breast cancer patients.
Anand A; Anand A
J Natl Cancer Inst; 1995 Nov; 87(21):1642. PubMed ID: 7563210
[No Abstract] [Full Text] [Related]
6. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
[TBL] [Abstract][Full Text] [Related]
7. Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxel.
Ishitobi M; Shin E; Kikkawa N
Int J Clin Oncol; 2001 Feb; 6(1):55-8. PubMed ID: 11706529
[TBL] [Abstract][Full Text] [Related]
8. Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel.
Lin YC; Chang HK; Wang CH; Chen JS; Liaw CC
Anticancer Drugs; 2000 Sep; 11(8):617-21. PubMed ID: 11081452
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
Ravdin PM
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-18-S10-21. PubMed ID: 9275002
[TBL] [Abstract][Full Text] [Related]
10. Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer.
Brodowicz T; Koestler WJ; Tomek S; Vaclavik I; Herscovici V; Wiltschke C; Steger GG; Zielinski CC
Anticancer Drugs; 2000 Mar; 11(3):149-53. PubMed ID: 10831273
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel in patients with anthracycline-resistant advanced breast cancer.
Vici P; Belli F; Di Lauro L; Amodio A; Conti F; Foggi P; Gionfra T; Morelli MF; Botti C; Ferraironi A; Lopez M
Oncology; 2001; 60(1):60-5. PubMed ID: 11150910
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel is a potent cytotoxic drug in the treatment of advanced breast cancer.
Van Vaerenbergh W; Paridaens R; Thomas J; Wildiers J; Van Oosterom A
Acta Clin Belg; 1998 Aug; 53(4):264-9. PubMed ID: 9795447
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
Ravdin PM; Burris HA; Cook G; Eisenberg P; Kane M; Bierman WA; Mortimer J; Genevois E; Bellet RE
J Clin Oncol; 1995 Dec; 13(12):2879-85. PubMed ID: 8523050
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Chan S
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
Ferraresi V; Milella M; Vaccaro A; D'Ottavio AM; Papaldo P; Nisticò C; Thorel MF; Marsella A; Carpino A; Giannarelli D; Terzoli E; Cognetti F
Am J Clin Oncol; 2000 Apr; 23(2):132-9. PubMed ID: 10776972
[TBL] [Abstract][Full Text] [Related]
18. [A case of docetaxel-resistant breast cancer responsive to paclitaxel therapy].
Oura S; Tanino H; Yoshimasu T; Sakurai T; Nakamura T; Kokawa Y; Matsuyama K; Naito Y
Gan To Kagaku Ryoho; 2001 Apr; 28(4):511-4. PubMed ID: 11329786
[TBL] [Abstract][Full Text] [Related]
19. Taxoids: effective agents in anthracycline-resistant breast cancer.
Ravdin PM
Semin Oncol; 1995 Dec; 22(6 Suppl 13):29-34. PubMed ID: 8604450
[TBL] [Abstract][Full Text] [Related]
20. Single-agent docetaxel (Taxotere) in randomized phase III trials.
Burris HA
Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
